Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk

References

• Bayer Pharma AG[Xarelto®] Annex I. Summary of Product CharacteristicsLeverkusenBayer Pharma AG2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdfAccessed November 15, 2013
   Google Scholar
• Janssen Pharmaceuticals Inc[Xarelto®] Highlights of Prescribing InformationTitusville, NJJanssen Pharmaceuticals Inc2013 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202439s008lbl.pdfAccessed December 22, 2013
   Google Scholar
• PerzbornERoehrigSStraubAKubitzaDMisselwitzFThe discovery and development of rivaroxaban, an oral, direct factor Xa inhibitorNat Rev Drug Discov2011101617521164526
   PubMed Web of Science ®Google Scholar
• CammAJLipGYDe CaterinaRESC Committee for Practice Guidelines (CPG)2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm AssociationEur Heart J201233212719274722922413
   PubMed Web of Science ®Google Scholar
• GageBFWatermanADShannonWValidation of clinical classification schemes for predicting stroke. Results from the National Registry of Atrial FibrillationJAMA2001285222864287011401607
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSRE-LY Steering Committee and InvestigatorsDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJARISTOTLE Committees and InvestigatorsApixaban versus warfarin in patients with atrial fibrillationN Engl J Med20113651198199221870978
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJROCKET AF InvestigatorsRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med20113651088389121830957
   PubMed Web of Science ®Google Scholar
• FoxKAPicciniJPWojdylaDPrevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairmentEur Heart J201132192387239421873708
   PubMed Web of Science ®Google Scholar
• HankeyGJPatelMRStevensSRROCKET AF Steering Committee InvestigatorsRivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AFLancet Neurol201211431532222402056
   PubMed Web of Science ®Google Scholar
• MahaffeyKWWhiteHDNesselCCIschemic cardiac outcomes in patients with AF treated with vitamin K antagonism or Factor Xa inhibition: results from the ROCKET AF trialCirculation2011124Suppl 21A13482 Abstract
   Web of Science ®Google Scholar
• MueckWErikssonBIBauerKAPopulation pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct factor Xa inhibitor – in patients undergoing major orthopaedic surgeryClin Pharmacokinet200847320321618307374
   PubMed Web of Science ®Google Scholar
• MueckWLensingAWAgnelliGDecoususHPrandoniPMisselwitzFRivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke preventionClin Pharmacokinet2011501067568621895039
   PubMed Web of Science ®Google Scholar
• GraffJvon HentigNMisselwitzFEffects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activityJ Clin Pharmacol200747111398140717873238
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMVoithBZuehlsdorfMWensingGSafety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitorClin Pharmacol Ther200578441242116198660
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMMueckWEffects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitorBr J Clin Pharmacol201070570371221039764
   PubMed Web of Science ®Google Scholar
• HelouRShould we continue to use the Cockcroft-Gault formula?Nephron Clin Pract20101163c172c185 discussion c18620606477
   PubMedGoogle Scholar
• CammAJKirchhofPLipGYEuropean Heart Rhythm AssociationEuropean Association for Cardio-Thoracic SurgeryGuidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)Eur Heart J201031192369242920802247
   PubMed Web of Science ®Google Scholar
• LeveyASCoreshJBalkENational Kidney FoundationNational Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratificationAnn Intern Med2003139213714712859163
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMRothAMueckWDose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjectsCurr Med Res Opin200824102757276518715524
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMWensingGVoithBZuehlsdorfMSafety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjectsEur J Clin Pharmacol2005611287388016328318
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMRothAMueckWThe influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct Factor Xa inhibitorJ Clin Pharmacol201353324925523381840
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMZuehlsdorfMMueckWBody weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjectsJ Clin Pharmacol200747221822617244773
   PubMed Web of Science ®Google Scholar
• HoriMMatsumotoMTanahashiNJ-ROCKET AF Study InvestigatorsRivaroxaban vs warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF studyCirc J20127692104211122664783
   PubMed Web of Science ®Google Scholar
• MueckWStampfussJKubitzaDBeckaMClinical pharmacokinetic and pharmacodynamic profile of rivaroxabanClin Pharmacokinet10.1007/s40262-013-0100-7
   Web of Science ®Google Scholar
• PughRNMurray-LyonIMDawsonJLTransection of the oesophagus for bleeding oesophageal varicesBr J Surg19736086466494541913
   PubMed Web of Science ®Google Scholar
• KubitzaDRothABeckaMEffect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitorBr J Clin Pharmacol2013761899823294275
   PubMed Web of Science ®Google Scholar
• GoodmanSGWojdylaDMWhiteHDPredictors of major bleeding risk: insights from the rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)Circulation2011124Suppl 21A16903 Abstract
   Google Scholar
• MueckWKubitzaDBeckaMCo-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjectsBr J Clin Pharmacol201376345546623305158
   PubMed Web of Science ®Google Scholar
• AbrahamNSHlatkyMAAntmanEMACCF/ACG/AHAACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus DocumentsCirculation2010122242619263321060077
   PubMed Web of Science ®Google Scholar
• HeidbuchelHVerhammePAlingsMEuropean Heart Rhythm AssociationEuropean Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillationEuropace201315562565123625942
   PubMed Web of Science ®Google Scholar
• KellerCMatzdorffACKemkes-MatthesBPharmacology of warfarin and clinical implicationsSemin Thromb Hemost1999251131610327215
   PubMed Web of Science ®Google Scholar
• TurpieAGKreutzRLlauJNorrvingBHaasSManagement consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitorThromb Haemost2012108587688623014816
   PubMed Web of Science ®Google Scholar
• LansbergMGO’DonnellMJKhatriPAmerican College of Chest PhysiciansAntithrombotic and Thrombolytic Therapy for Ischemic Stroke: Antithrombotic Therapy and Prevention of Thrombosis. 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest2012141Suppl 2e601Se636S22315273
   PubMed Web of Science ®Google Scholar
• The European Stroke Organisation (ESO) Executive CommitteeESO Writing CommitteeGuidelines for management of ischaemic stroke and transient ischaemic attack 2008Cerebrovasc Dis200825545750718477843
   PubMed Web of Science ®Google Scholar
• European Stroke OrganisationConsensus statement 2012: Update on Intravenous ThrombolysisKarolinskaEuropean Stroke Organisation2012 Available from: http://www.strokeupdate.org/Cons_Reperf_IVT_2012.aspxAccessed December 20, 2013
   Google Scholar
• AdamsHPdel ZoppoGAlbertsMJAmerican Heart Association/American Stroke Association Stroke CouncilAmerican Heart Association/American Stroke Association Clinical Cardiology CouncilAmerican Heart Association/American Stroke Association Cardiovascular Radiology and Intervention CouncilAtherosclerotic Peripheral Vascular Disease Working GroupQuality of Care Outcomes in Research Interdisciplinary Working GroupGuidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologistsCirculation200711520e478e53417515473
   PubMed Web of Science ®Google Scholar
• PaciaroniMAgnelliGCoreaFEarly hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter studyStroke20083982249225618535273
   PubMed Web of Science ®Google Scholar
• LipGYHuberKAndreottiFEuropean Society of Cardiology Working Group on ThrombosisManagement of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stentingThromb Haemost20101031132820062939
   PubMed Web of Science ®Google Scholar
• HammCWBassandJPAgewallSESC Committee for Practice GuidelinesESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)Eur Heart J201132232999305421873419
   PubMed Web of Science ®Google Scholar
• VandvikPOLincoffAMGoreJMAmerican College of Chest PhysiciansPrimary and Secondary Prevention of Cardiovascular Disease: Antithrombotic Therapy and Prevention of Thrombosis. 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest2012141Suppl 2e637Se668S22315274
   PubMed Web of Science ®Google Scholar
• MegaJLBraunwaldEWiviottSDATLAS ACS 2–TIMI 51 InvestigatorsRivaroxaban in patients with a recent acute coronary syndromeN Engl J Med2012366191922077192
   PubMed Web of Science ®Google Scholar
• EerenbergESKamphuisenPWSijpkensMKMeijersJCBullerHRLeviMReversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjectsCirculation2011124141573157921900088
   PubMed Web of Science ®Google Scholar
• MarluRHodajEParisAEffect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteersThromb Haemost2012108221722422627883
   PubMed Web of Science ®Google Scholar
• SchulmanSResumption of oral anticoagulation after warfarin-associated intracerebral hemorrhage: noStroke201142123663366422052515
   PubMed Web of Science ®Google Scholar
• SteinerTResumption of oral anticoagulation after warfarin-associated intracerebral hemorrhage: yesStroke201142123661366222052514
   PubMed Web of Science ®Google Scholar
• MajeedAKimYKRobertsRSHolmströmMSchulmanSOptimal timing of resumption of warfarin after intracranial hemorrhageStroke201041122860286621030703
   PubMed Web of Science ®Google Scholar
• Lindhoff-LastEAnsellJSpiroTSamamaMMLaboratory testing of rivaroxaban in routine clinical practice: when, how, and which assaysAnn Med2013455–642342923746003
   PubMed Web of Science ®Google Scholar
• Lindhoff-LastESamamaMMOrtelTLWeitzJISpiroTEAssays for measuring rivaroxaban: their suitability and limitationsTher Drug Monit201032667367920844464
   PubMed Web of Science ®Google Scholar
• SamamaMMAmiralJGuinetCPerzbornEDepasseFAn optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasmaThromb Haemost201010451078107920806114
   PubMed Web of Science ®Google Scholar
• SamamaMMContantGSpiroTERivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial LaboratoriesEvaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controlsThromb Haemost2012107237938722187012
   PubMed Web of Science ®Google Scholar
• AsmisLMAlberioLAngelillo-ScherrerARivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratoriesThromb Res2012129449249821840043
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim International GmbH[Pradaxa®] Annex I. Summary of Product CharacteristicsIngelheim am RheinBoehringer Ingelheim International GmbH2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdfAccessed December 22, 2013
   Google Scholar
• Bristol-Myers Squibb/Pfizer EEIG[Eliquis®] Annex I. Summary of Product CharacteristicsUxbridgeBristol-Myers Squibb2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdfAccessed December 22, 2013
   Google Scholar
• PistersRLaneDANieuwlaatRA novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart SurveyChest201013851093110020299623
   PubMed Web of Science ®Google Scholar